Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe : The PanCareSurFup study
(2023) In Cancer 129(3). p.426-440- Abstract
Background: Survivors of Hodgkin lymphoma (HL) are at risk of developing non-Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. Methods: The Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 69,460 five-year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks... (More)
Background: Survivors of Hodgkin lymphoma (HL) are at risk of developing non-Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. Methods: The Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 69,460 five-year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression. Results: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5). Conclusions: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy.
(Less)
- author
- organization
- publishing date
- 2023-02
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- childhood cancer survivors, Hodgkin lymphoma, late effects, non-Hodgkin lymphoma, second cancers, subsequent primary lymphoma
- in
- Cancer
- volume
- 129
- issue
- 3
- pages
- 15 pages
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85142914919
- pmid:36444554
- ISSN
- 0008-543X
- DOI
- 10.1002/cncr.34561
- language
- English
- LU publication?
- yes
- id
- 5b09509b-f772-40f2-bb8e-a334183bbda3
- date added to LUP
- 2023-01-30 15:30:44
- date last changed
- 2024-06-09 12:18:15
@article{5b09509b-f772-40f2-bb8e-a334183bbda3,
abstract = {{<p>Background: Survivors of Hodgkin lymphoma (HL) are at risk of developing non-Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. Methods: The Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 69,460 five-year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression. Results: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5). Conclusions: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy.</p>}},
author = {{Dudley, Isabelle M. and Sunguc, Ceren and Heymer, Emma J. and Winter, David L. and Teepen, Jop C. and Belle, Fabiën N. and Bárdi, Edit and Bagnasco, Francesca and Gudmundsdottir, Thorgerdur and Skinner, Roderick and Michel, Gisela and Byrne, Julianne and Øfstaas, Hilde and Jankovic, Momcilo and Mazić, Maja Česen and Mader, Luzius and Loonen, Jaqueline and Garwicz, Stanislaw and Wiebe, Thomas and Alessi, Daniela and Allodji, Rodrigue S. and Haddy, Nadia and Grabow, Desiree and Kaatsch, Peter and Kaiser, Melanie and Maule, Milena M. and Jakab, Zsuzsanna and Gunnes, Maria Winther and Terenziani, Monica and Zaletel, Lorna Zadravec and Kuehni, Claudia E. and Haupt, Riccardo and de Vathaire, Florent and Kremer, Leontien C. and Lähteenmäki, Päivi M. and Winther, Jeanette F. and Hjorth, Lars and Hawkins, Michael M. and Reulen, Raoul C.}},
issn = {{0008-543X}},
keywords = {{childhood cancer survivors; Hodgkin lymphoma; late effects; non-Hodgkin lymphoma; second cancers; subsequent primary lymphoma}},
language = {{eng}},
number = {{3}},
pages = {{426--440}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Cancer}},
title = {{Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe : The PanCareSurFup study}},
url = {{http://dx.doi.org/10.1002/cncr.34561}},
doi = {{10.1002/cncr.34561}},
volume = {{129}},
year = {{2023}},
}